CannapharmarxCPMD Debt-to-EBITDA is 12.95 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Cannapharmarx ranks worse than 144927.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cannapharmarx's Debt-to-EBITDA or its related term are showing as below:
CPMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.65 Med: -1.54 Max: 2.35
Current: -2.56
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cannapharmarx was 2.35. The lowest was -9.65. And the median was -1.54.
CPMD's Debt-to-EBITDA is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs CPMD: -2.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cannapharmarx Debt-to-EBITDA Related Terms
Cannapharmarx Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cannapharmarx's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPMD vs NPHC, BSPK, UPC: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannapharmarx Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cannapharmarx's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cannapharmarx (CPMD) has a Debt-to-EBITDA of 12.95 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cannapharmarx. According to the industry distribution chart, Cannapharmarx ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Cannapharmarx's Debt-to-EBITDA too high?
Cannapharmarx's current Debt-to-EBITDA is 12.95. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Cannapharmarx's value of 12.95 is 675.4% above this industry median. Based on the distribution chart, Cannapharmarx ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannapharmarx's Debt-to-EBITDA compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, Cannapharmarx ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Cannapharmarx in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Cannapharmarx's value of 12.95 is 675.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannapharmarx's current Debt-to-EBITDA of 12.95 is 675.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cannapharmarx. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannapharmarx's current Debt-to-EBITDA is 12.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannapharmarx stock overvalued right now?
Cannapharmarx (CPMD) has a current Debt-to-EBITDA of 12.95. The current Debt-to-EBITDA is 12.95 and 675.4% above the Drug Manufacturers industry median of 1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cannapharmarx (CPMD), the current Debt-to-EBITDA is 12.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. The products of the company are Unique Genetics, Craft Products, and Medical Cannabis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPMD has been successfully added to your 